GlassScriptPhysician profile
Christopher L Richards
NPI 1376539551
$11,723.90
in general payments reported to CMS, 2019-2025
47 companies · $3,118 in 2025
The $3,118 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,111 · 2021: $124 · 2022: $318 · 2023: $2,156 · 2024: $2,896 · 2025: $3,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,146 · Education: $24.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,146.47 |
| Education | $24.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,779.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,606.13 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,154.31 | 2023-2025 | |
| Glaxosmithkline, LLC. | $983.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $704.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $573.67 | 2019-2025 | |
| Amgen INC. | $572.94 | 2019-2025 | Prolia, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $431.35 | 2019-2025 | Jardiance |
| Dexcom, INC. | $417.05 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Merck Sharp & Dohme LLC | $279.36 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Ardelyx, INC. | $269.95 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $269.52 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $207.27 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $206.48 | 2019-2025 | Zoryve |
| Shield Therapeutics INC | $193.98 | 2023-2025 | Accrufer |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.